Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index
Search
EN

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «RHo (D) immune globulin»

RHo (D) immune globulin

Generic Name: RHo (D) immune globulin (ROE D im MYOON GLOB yoo lin)Brand names: HyperRHO S/D Full Dose, HyperRHO S/D Mini Dose, MicRhoGAM, MicRhoGAM Ultra-Filtered Plus, RhoGAM, RhoGAM Ultra-Filtered Plus, Rhophylac, WinRho SDF, ...show all 17 brand names.Gamulin Rh, Mini-Gamulin Rh, HypRho-D Mini-Dose, BayRHo-D, BayRHo-D Full Dose, BayRHo-D Mini-Dose, D-Gam Anti-D, Partobulin SDF, Liberim D

What is Rho(D) IG?

Rho(D) immune globulin (Rho(D) IG) is a sterilized solution made from human blood. Rh is a substance that most people have in their blood (Rh positive) but some people don't (Rh negative). A person who is Rh negative can be exposed to Rh positive blood through a mismatched blood transfusion or during pregnancy when the baby has the opposite blood type. When this exposure happens, the Rh negative blood will respond by making antibodies that will try to destroy the Rh positive blood cells. This can cause medical problems such as anemia (loss of red blood cells), kidney failure, or shock.

Rho(D) IG is used to prevent an immune response to Rh positive blood in people with an Rh negative blood type. Rho(D) IG may also be used in the treatment of immune thrombocytopenic purpura (ITP).

Rho(D) IG may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Rho(D) IG?

While you are being treated with this medication, call your doctor right away if you have fever, chills, shaking, back pain, a change in the color of your urine or how much you urinate, sudden weight gain, or swelling in your hands, ankles, or feet. Do not receive live-virus vaccines such as measles, mumps, rubella, or chicken pox (also called MMR or Varivax) for at least 3 months after treatment with Rho(D) IG. These vaccines may not work properly during Rho(D) IG treatment and shortly afterward.

Rho(D) IG is made from human plasma (part of the blood) and may contain viruses and other infectious agents that can cause disease. Although Rho(D) IG is screened, tested, and treated to reduce the risk of it containing anything that could cause disease, there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication.

If you are an Rh-negative woman and you become pregnant, you must tell your doctor if you have ever been exposed to Rh-positive blood in your lifetime. This includes exposure from a mismatched blood transfusion, or exposure during your first pregnancy. Your history of exposure and treatment will be extremely important to each and every one of your pregnancies.

What should I discuss with my healthcare provider before I receive Rho(D) IG?

You should not use this medication if you are allergic to it.

If you have any of these other conditions, you may need a dose adjustment or special tests to safely use this medication:

  • an allergy to human immune globulin;

  • a bleeding disorder (such as hemophilia); or

  • immune globulin A (IgA) deficiency.

Rho(D) IG is used during and after pregnancy. This medication is not known to be harmful to a baby during pregnancy or while breast-feeding.

If you are receiving this medication to treat a mismatched blood transfusion, tell your doctor if you are pregnant or if you ever plan to become pregnant.

If you are an Rh-negative woman and you become pregnant, you must tell your doctor if you have ever been exposed to Rh-positive blood in your lifetime. This includes exposure from a mismatched blood transfusion, or exposure during your first pregnancy. Your history of exposure and treatment will be extremely important to each and every one of your pregnancies.

Rho(D) IG is made from human plasma (part of the blood) and may contain viruses and other infectious agents that can cause disease. Although Rho(D) IG is screened, tested, and treated to reduce the risk of it containing anything that could cause disease, there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication.

How is Rho(D) IG given?

Rho(D) IG is given as an injection into a muscle or a vein. You will receive this injection while you are in a hospital or clinic.

For treatment during pregnancy, this medication is usually given at regular intervals during the last half of the pregnancy, and again after the baby is born.

For treatment of a mismatched blood transfusion, the medication is given when symptoms of an immune response appear (when the body starts making Rh antibodies).

To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Your kidney or liver function may also need to be tested. It is important that you not miss any scheduled visits to your doctor.

What happens if I miss a dose?

Contact your doctor if you have a missed a dose of Rho(D) IG. Try to keep all appointments so you do not miss a dose of this medication.

What happens if I overdose?

Seek emergency medical attention if you think you have received too much of this medicine.

Since Rho(D) IG is given by a healthcare professional, an overdose is not likely to occur.

What should I avoid while receiving Rho(D) IG?

Do not receive live-virus vaccines such as measles, mumps, rubella, or chicken pox (also called MMR or Varivax) for at least 3 months after treatment with Rho(D) IG. These vaccines may not work properly during Rho(D) IG treatment and shortly afterward.

Rho(D) IG side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:
  • fever, chills, or shaking;

  • urinating less than normal;

  • a change in color of your urine;

  • sudden weight gain, swelling in your hands, feet, or ankles;

  • back pain; or

  • shortness of breath.

Less serious side effects may include:

  • muscle aches or pains;

  • headache;

  • feeling tired or light-headed;

  • nausea, vomiting; or

  • pain or tenderness where the injection is given.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

RHo (D) immune globulin Dosing Information

Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic Purpura:

Treatment must be given by intravenous administration (not all Rho (D) immune globulin products are approved for IV administration)Initial dose: 50 mcg/kg (250 intl units/kg) body weight IV once. The initial dose, if desired, may be administered in two divided doses given on separate days.Prior to administering the initial dose, the patient must be confirmed as Rho (D) positive.Subsequent dosing: 25 to 60 mcg/kg (125 to 300 intl units/kg) body weight IV with the exact dose and frequency to be determined by the clinical response of the patient which is assessed by platelet counts, red cell counts, hemoglobin (Hgb), and reticulocyte levels. Guidelines for maintenance IV therapy:If the patient responded to the initial dose with a satisfactory increase in platelets: 25 to 60 mcg/kg (125 to 300 intl units/kg) with the exact dose to be based on the platelet and Hgb levels.If the patient did not respond to the initial dose, subsequent doses are to be as follows (based on the Hgb level of the patient):Hgb <8 g/dL use with extreme caution.Hgb 8 to 10 g/dL administer 25 to 40 mcg/kg (125 to 200 intl units/kg).Hgb >10 g/dL administer 50 to 60 mcg/kg (250 to 300 intl units/kg).

Usual Adult Dose for Rh-Isoimmunization:

Dose and route varies for each product.Routine antepartum prophylaxis and postpartum prevention:WinRho: 300 mcg (1500 intl units) IV or IM at 28 weeks' gestation. If administered early in the pregnancy, repeat dose at 12-week intervals until delivery to maintain an adequate level of passively acquired anti-Rh. RhoGam: 300 mcg IM once at 26 to 28 weeks' gestation. If administered earlier than 26 to 28 weeks' gestation, repeat dose at 12-week intervals until delivery to maintain an adequate level of passively acquired anti-Rh.Rhophylac: 300 mcg (1500 intl units) IV or IM at 28 to 30 weeks' gestation.HyperRHO S/D Full Dose: 1500 intl units IM at approximately 28 weeks' gestation. This dose must be repeated preferably within 72 hours following delivery, if the infant is Rh positive.Postpartum prevention:WinRho: 120 mcg (600 intl units) IV or IM, administered to the mother, within 72 hours of birth after an Rh incompatible delivery. Administration within 72 hours is preferred; however, WinRho may be administered up to 28 days postpartum.RhoGam: 300 mcg IM, administered to the mother, within 72 hours of birth after an Rh incompatible delivery. If delivery occurs within 3 weeks after last antepartum dose, the postpartum dose may be withheld, but a test for FMH should be performed to determine if exposure to greater than 15 mL of red cells has occurred.Rhophylac: 300 mcg (1500 intl units) IV or IM, administered to the mother, within 72 hours of birth after an Rh incompatible delivery.HyperRHO S/D Full Dose: 1500 intl units IM within 72 hours of delivery. It may be given beyond the 72-hour period, but a lesser degree of protection is afforded.Obstetrical conditions:WinRho:Threatened abortion at any time during pregnancy: 300 mcg (1500 intl units) IV or IM immediately after event.Amniocentesis and chorionic villus sampling prior to 34 weeks' gestation: 300 mcg (1500 intl units) IV or IM with dose repeated every 12 weeks until delivery.Abortion, amniocentesis, or any other manipulation after 34 weeks gestation: 120 mcg (600 intl units) IV or IM within 72 hours of event.MICRhogam: 50 mcg IM within 72 hours following pregnancy termination occurring up to and including 12 weeks gestation.RhoGam:Amniocentesis, chorionic villus sampling, percutaneous umbilical blood sampling, abdominal trauma, obstetrical manipulation, ectopic pregnancy, abortion or termination of pregnancy after 12 weeks gestation: 300 mcg IM within 72 hours of event.Threatened abortion at any stage of gestation with continuation of pregnancy: 300 mcg IM within 72 hours of event.Fetal-maternal hemorrhage less than 15 mL Rh-positive red blood cells: 300 mcg IM within 72 hours of event.Fetal-maternal hemorrhage of greater than 15 mL Rh-positive red blood cells: a dose greater than 20 mcg/mL Rh-positive red blood cells IM within 72 hours of event may be necessary.MICRhogam:Abortion or termination of pregnancy up to and including 12 weeks gestation: 50 mcg IM within 72 hours of event.Rhophylac:Miscarriage, abortion, threatened abortion, ectopic pregnancy, hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage: 300 mcg (1500 intl units) IV or IM within 72 hours of event.Amniocentesis, chorionic biopsy, obstetric manipulative procedures, or any other invasive procedure performed during pregnancy: 300 mcg (1500 intl units) IV or IM within 72 hours of event.Fetal-maternal hemorrhage less than 15 mL Rho (D) positive red blood cells: 300 mcg IV or IM within 72 hours of event.Fetal-maternal hemorrhage greater than 15 mL Rho (D) positive red blood cells: 20 mcg/mL cells IV or IM within 72 hours of event. If fetal red blood cells cannot be tested administer 600 mcg IV or IM within 72 hours of event.HyperRHO S/D Full Dose: Threatened abortion at any stage gestation with continuation of pregnancy: 1500 intl units IM within 72 hours of event.Miscarriage, abortion, or termination of ectopic pregnancy at or beyond 13 weeks' gestation: 1500 intl units IM.Amniocentesis at either 15 to 18 weeks' gestation of during the third trimester, or following abdominal trauma in the second or third trimester: 1500 intl units IM once, then another dose should be given at 26 to 28 weeks. A postpartum dose should be administered within 72 hours after delivery if the baby is Rh positive. If delivery occurs within 3 weeks after the last dose, the postpartum dose may be withheld unless there is a fetal-maternal hemorrhage in excess of 15 mL of red blood cells.Transfusion accidents or fetal-maternal hemorrhage:WinRho:Exposure to Rho (D) positive whole blood: 600 mcg (3000 intl units) IV every 8 hours until a total dose of 9 mcg (45 intl units)/mL blood is administered or 1200 mcg (6000 intl units) IM every 12 hours until a total dose of 12 mcg (60 intl units)/mL blood is administered. The total dose should be administered within 72 hours of exposure.Exposure to Rho (D) positive red blood cells: 600 mcg (3000 intl units) IV every 8 hours until a total dose of 18 mcg (90 intl units)/mL cells is administered or 1200 mcg (6000 intl units) IM every 12 hours until a total dose of 24 mcg (120 intl units)/mL cells is administered. The total dose should be administered within 72 hours of exposure.MICRhogam:Less than 2.5 mL of Rh-incompatible red blood cells administered: 50 mcg IM within 72 hours of event.RhoGam:Greater than 2.5 mL of Rh-incompatible red blood cells administered: 300 mcg IM within 72 hours of event.Rhophylac:Exposure to Rho (D) positive whole blood: 20 mcg (100 intl units)/2 mL transfused blood IV or IM within 72 hours of event.Exposure to Rho (D) positive red blood cells: 20 mcg (100 intl units)/ml cells IV or IM within 72 hours of event.HyperRHO S/D Full Dose:Exposure to Rho (D) positive red blood cells: the volume of red blood cells divided by 15 mL provides the number of vials/syringes (rounded to the nearest larger whole number) to be administered as soon as possible, but within 72 hours of event.

Usual Pediatric Dose for Idiopathic (Immune) Thrombocytopenic Purpura:

Treatment must be given by intravenous administration (not all Rho (D) immune globulin products are approved for IV administration)Initial dose: 50 mcg/kg (250 intl units/kg) body weight IV once. The initial dose, if desired, may be administered in two divided doses given on separate days.Prior to administering the initial dose, the patient must be confirmed as Rho (D) positive.Subsequent dosing: 25 to 60 mcg/kg (125 to 300 intl units/kg) body weight IV with the exact dose and frequency to be determined by the clinical response of the patient which is assessed by platelet counts, red cell counts, hemoglobin (Hgb), and reticulocyte levels. Guidelines for maintenance IV therapy:If the patient responded to the initial dose with a satisfactory increase in platelets: 25 to 60 mcg/kg (125 to 300 intl units/kg) with the exact dose to be based on the platelet and Hgb levels.If the patient did not respond to the initial dose, subsequent doses are to be as follows (based on the Hgb level of the patient):Hgb <8 g/dL use with extreme caution.Hgb 8 to 10 g/dL administer 25 to 40 mcg/kg (125 to 200 intl units/kg).Hgb >10 g/dL administer 50 to 60 mcg/kg (250 to 300 intl units/kg).

What other drugs will affect Rho(D) IG?

There may be other drugs that can interact with Rho(D) IG. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Where can I get more information?

  • Your doctor or pharmacist can provide more information about Rho(D) IG.
  • Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 1996-2006 Cerner Multum, Inc. Version: 2.01. Revision Date: 08/26/2009 9:58:36 AM.
  • BayRho-D Advanced Consumer (Micromedex) - Includes Dosage Information
  • MICRhoGAM MedFacts Consumer Leaflet (Wolters Kluwer)
  • RhoGAM Ultra-Filtered PLUS Prescribing Information (FDA)
  • Rhophylac MedFacts Consumer Leaflet (Wolters Kluwer)
  • Rhophylac Prescribing Information (FDA)
  • Rhophylac Consumer Overview
  • WinRho SDF MedFacts Consumer Leaflet (Wolters Kluwer)

Comment «RHo (D) immune globulin»